With would-be competition in the wings from Thar Pharmaceuticals Inc. in complex regional pain syndrome (CRPS), Axsome Therapeutics Inc. filed for an IPO that would raise as much as $57.5 million to fund AXS-02 (disodium zoledronate) in a phase III trial called Create-1 that began over the summer for that indication, and to boost efforts with AXS-05, a fixed-dose combination of dextromethorphan (DM) and bupropion, slated to enter phase III experiments next year in treatment-resistant depression (TRD).